Form 4: Apellis GC Sells 5,000 Shares via 10b5-1 Plan
Insider Transaction Report
Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock for $27.80 per share as part of a pre-arranged 10b5-1 trading plan.
Summary
- David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (APLS), reported a sale of common stock.
- The transaction involved 5,000 shares sold at a price of $27.80 per share.
- The sale occurred on August 18, 2025.
- This transaction was a scheduled sale executed under a Rule 10b5-1 trading plan established on March 3, 2025.
- Following the sale, Mr. Watson directly owns 123,730 shares of common stock.
- He also indirectly holds 10,000 shares in a custodial account for minor children and 70,136 shares through The David O. Watson Irrevocable Trust of 2023.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is generally considered a neutral event as it is not indicative of new information or a change in sentiment regarding the company's prospects.
Future Outlook
N/A
Industry Context
This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.
Related Party Transactions
- Indirect ownership of 10,000 shares in a custodial account held by the reporting person for the sole benefit of his minor children.
- Indirect ownership of 70,136 shares held by The David O. Watson Irrevocable Trust of 2023, where William Zorn is the trustee. The reporting person disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the 10b5-1 trading plan establishment. |
| 08/18/2025 | Date of the common stock transaction (sale). |
| 08/19/2025 | Date the Form 4 was signed by the reporting person. |
Recommendation
holdThe filing is a routine Form 4 reporting a pre-scheduled insider stock sale under a 10b5-1 plan. Such transactions are generally not indicative of new material information about the company's performance or outlook and therefore do not typically warrant a change in investment recommendation.
Keywords
Apellis Pharmaceuticals, APLS, Insider Trading, Form 4, Stock Sale, David O. Watson, 10b5-1 Plan, General Counsel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.